Biodexa Accounts Payable vs Short Long Term Debt Total Analysis
BDRX Stock | 4.80 0.18 3.61% |
Biodexa Pharmaceticals financial indicator trend analysis is way more than just evaluating Biodexa Pharmaceticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Biodexa Pharmaceticals is a good investment. Please check the relationship between Biodexa Pharmaceticals Accounts Payable and its Short Long Term Debt Total accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biodexa Pharmaceticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Biodexa Stock please use our How to Invest in Biodexa Pharmaceticals guide.
Accounts Payable vs Short Long Term Debt Total
Accounts Payable vs Short Long Term Debt Total Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Biodexa Pharmaceticals Accounts Payable account and Short Long Term Debt Total. At this time, the significance of the direction appears to have strong relationship.
The correlation between Biodexa Pharmaceticals' Accounts Payable and Short Long Term Debt Total is 0.62. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Short Long Term Debt Total in the same time period over historical financial statements of Biodexa Pharmaceticals, assuming nothing else is changed. The correlation between historical values of Biodexa Pharmaceticals' Accounts Payable and Short Long Term Debt Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Biodexa Pharmaceticals are associated (or correlated) with its Short Long Term Debt Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Long Term Debt Total has no effect on the direction of Accounts Payable i.e., Biodexa Pharmaceticals' Accounts Payable and Short Long Term Debt Total go up and down completely randomly.
Correlation Coefficient | 0.62 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Accounts Payable
An accounting item on the balance sheet that represents Biodexa Pharmaceticals obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Biodexa Pharmaceticals are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Short Long Term Debt Total
Most indicators from Biodexa Pharmaceticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Biodexa Pharmaceticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biodexa Pharmaceticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Biodexa Stock please use our How to Invest in Biodexa Pharmaceticals guide.At this time, Biodexa Pharmaceticals' Enterprise Value Over EBITDA is fairly stable compared to the past year. Enterprise Value Multiple is likely to rise to 0.56 in 2024, whereas Selling General Administrative is likely to drop slightly above 3.9 M in 2024.
Biodexa Pharmaceticals fundamental ratios Correlations
Click cells to compare fundamentals
Biodexa Pharmaceticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Biodexa Pharmaceticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 30.9M | 9.8M | 12.9M | 5.5M | 10.5M | 20.9M | |
Other Current Liab | 761K | 2.4M | 1.2M | 1.3M | 5.0M | 5.3M | |
Total Current Liabilities | 5.7M | 3.0M | 1.8M | 1.9M | 5.6M | 3.8M | |
Total Stockholder Equity | 19.6M | 6.7M | 10.5M | 3.2M | 4.7M | 4.4M | |
Property Plant And Equipment Net | 2.2M | 542K | 1.2M | 831K | 571K | 542.5K | |
Net Debt | (4.8M) | (7.3M) | (9.3M) | (2.2M) | (5.5M) | (5.8M) | |
Retained Earnings | (99.8M) | (122.4M) | (127.8M) | (135.3M) | (144.8M) | (137.5M) | |
Accounts Payable | 4.5M | 337K | 485K | 339K | 314K | 298.3K | |
Cash | 10.9M | 7.5M | 10.1M | 2.8M | 6.0M | 8.0M | |
Non Current Assets Total | 17.2M | 542K | 1.2M | 837K | 3.5M | 3.3M | |
Non Currrent Assets Other | 2.6M | (542K) | (1.2M) | (837K) | (753.3K) | (715.6K) | |
Cash And Short Term Investments | 10.9M | 7.5M | 10.1M | 2.8M | 6.0M | 8.0M | |
Non Current Liabilities Total | 5.7M | 110K | 619.5K | 463K | 295K | 280.3K | |
Other Current Assets | 2.8M | 258K | 607K | 376K | 355K | 337.3K | |
Other Stockholder Equity | 65.9M | 74.4M | 85.2M | 83.7M | 86.7M | 59.2M | |
Total Liab | 11.3M | 3.1M | 2.5M | 2.4M | 5.9M | 5.8M | |
Total Current Assets | 13.7M | 9.3M | 11.8M | 4.7M | 7.0M | 10.0M | |
Intangible Assets | 14.2M | 10.1M | 10.1M | 6K | 2.9M | 2.8M | |
Short Long Term Debt Total | 6.1M | 260K | 766K | 624K | 464K | 440.8K | |
Net Receivables | 22K | 95K | 33K | 329K | 704K | 455.7K | |
Liabilities And Stockholders Equity | 30.9M | 9.8M | 12.9M | 5.5M | 10.5M | 10.0M | |
Accumulated Other Comprehensive Income | 56.4M | 53.7M | 53.5M | 53.0M | 61.5M | 53.6M | |
Short Term Debt | 412K | 200K | 146K | 161K | 169K | 307.8K | |
Common Stock | 23K | 63K | 98.5K | 1.1M | 1.2M | 1.2M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Biodexa Stock Analysis
When running Biodexa Pharmaceticals' price analysis, check to measure Biodexa Pharmaceticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biodexa Pharmaceticals is operating at the current time. Most of Biodexa Pharmaceticals' value examination focuses on studying past and present price action to predict the probability of Biodexa Pharmaceticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biodexa Pharmaceticals' price. Additionally, you may evaluate how the addition of Biodexa Pharmaceticals to your portfolios can decrease your overall portfolio volatility.